Skip to main content

Prazosin









Prazosin


From Wikipedia, the free encyclopedia

Jump to navigation
Jump to search
















































































































Prazosin
Prazosin.svg
Clinical data
Synonyms Minipress, Vasoflex, Lentopres, Hypovase, others

AHFS/Drugs.com
 Monograph
MedlinePlus a682245
License data


  • US FDA: Prazosin
Routes of
administration		 Oral
ATC code

  • C02CA01 (WHO)
Legal status
Legal status



  • UK: POM (Prescription only)


  • US: ℞-only




Pharmacokinetic data
Bioavailability ~60%
Protein binding 97%
Onset of action 30–90 minutes[1]
Elimination half-life
 2–3 hours
Identifiers
CAS Number

  • 19216-56-9 ☑Y

PubChem CID
  • 4893
IUPHAR/BPS
  • 503
DrugBank

  • DB00457 ☑Y
ChemSpider

  • 4724 ☑Y
UNII
  • XM03YJ541D
KEGG

  • D08411 ☑Y
ChEBI

  • CHEBI:8364 ☑Y
ChEMBL

  • ChEMBL2 ☑Y
ECHA InfoCard
100.038.971 Edit this at Wikidata
Chemical and physical data
Formula
C19H21N5O4
Molar mass 383.41 g·mol−1
3D model (JSmol)
  • Interactive image

.mw-parser-output .nobold{font-weight:normal}
  (verify)

Prazosin is a sympatholytic medication that is used to treat high blood pressure, anxiety, and posttraumatic stress disorder (PTSD).[2][3] Prazosin is an α1-blocker that acts as an inverse agonist at alpha-1 adrenergic receptors.[4] These receptors are found on vascular smooth muscle, where they are responsible for the vasoconstrictive action of norepinephrine.[3] They are also found throughout the central nervous system.[5]


As of 2013, prazosin is off-patent in the US, and the FDA has approved at least one generic manufacturer.




Contents






  • 1 Medical use


  • 2 Adverse effects


  • 3 Research


  • 4 References





Medical use[edit]


Prazosin is orally active and has a minimal effect on cardiac function due to its alpha-1 receptor selectivity. When prazosin is started, however, heart rate and contractility go up in order to maintain the pre-treatment blood pressures because the body has reached homeostasis at its abnormally high blood pressure. The blood pressure lowering effect becomes apparent when prazosin is taken for longer periods of time. The heart rate and contractility go back down over time and blood pressure decreases.


The antihypertensive characteristics of prazosin make it a second-line choice for the treatment of high blood pressure.[6]


Prazosin is also useful in treating urinary hesitancy associated with prostatic hyperplasia, blocking alpha-1 receptors, which control constriction of both the prostate and urethra. Although not a first line choice for either hypertension or prostatic hyperplasia, it is a choice for patients who present with both problems concomitantly.[6]


There is some evidence that this medication is effective in treating nightmares, mixed results in randomized control trials. Prazosin was, however, shown to be more effective when treating nightmares related to PTSD.[7]


The drug is usually recommended for severe stings from Indian Red Scorpion Hottentotta tamulus in Indian Subcontinent.[8][9][10]



Adverse effects[edit]


Common (4–10% frequency) side effects of prazosin include dizziness, headache, drowsiness, lack of energy, weakness, palpitations, and nausea.[2] Less frequent (1–4%) side effects include vomiting, diarrhea, constipation, edema, orthostatic hypotension, dyspnea, syncope, vertigo, depression, nervousness, and rash.[2] A very rare side effect of prazosin is priapism.[2][11] One phenomenon associated with prazosin is known as the "first dose response", in which the side effects of the drug – specifically orthostatic hypotension, dizziness, and drowsiness – are especially pronounced in the first dose.[2]


Orthostatic hypotension and syncope are associated with the body's poor ability to control blood pressure without active alpha-adrenergic receptors. Patients on prazosin should be told to rise to stand up slowly, since their poor baroreflex may cause them to faint if their blood pressure is not adequately maintained during standing. The nasal congestion is due to dilation of vessels in the nasal mucosa.



Research[edit]


Prazosin holds promise as a pharmacologic treatment for alcohol dependence after a 2009 pilot trial[12] was completed. A larger controlled Phase II "Clinical Trial of the Adrenergic Alpha-1 Antagonist Prazosin for Alcohol Dependence" was completed in 2018 and published in the American Journal of Psychiatry.[13]
While on the surface Prazosin showed an effect greater than placebo, the confidence intervals in the study vastly exceeded the difference, making the data from this study statistically unreliable.[14]


In cancer research, Prazosin triggered apoptosis of glioblastoma‐initiating cells and of their differentiated progeny, inhibited glioblastoma growth in orthotopic xenografts of patient‐derived glioblastoma‐initiating cells, and increased survival of glioblastoma‐bearing mice. Its activity occurred via a PKCδ‐dependent inhibition of the AKT pathway, which resulted in caspase‐3 activation. So, prazosin is a potential anti‐glioblastoma adjuvant drug.[15] Clinical trials will be initiated to confirm these findings. Understanding the mechanism of action of prazosin may pave the way for the development of new potential treatments also for other cancers, since other cancer cells as well display altered PKCδ signaling, including those in colorectal, pancreatic and liver cancer.[16]



References[edit]





  1. ^ Packer M, Meller J, Gorlin R, Herman MV (1979). "Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure". Circulation. 59 (3): 531–9. doi:10.1161/01.cir.59.3.531. PMID 761333..mw-parser-output cite.citation{font-style:inherit}.mw-parser-output q{quotes:"""""""'""'"}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-limited a,.mw-parser-output .cs1-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}


  2. ^ abcde "Minipress Prescribing Information" (PDF). United States Food and Drug Administration. Pfizer. February 2015. Retrieved 3 June 2016.


  3. ^ ab "Prazosin: Clinical data". IUPHAR. International Union of Basic and Clinical Pharmacology. Retrieved 3 June 2016. This sympatholytic drug is used in the treatment of hypertension, anxiety and post-traumatic stress disorder. ... Antagonist of alpha-1 adrenoceptors on vascular smooth muscle, thereby inhibiting the vasoconstrictor effect of circulating and locally-released adrenaline and noradrenaline, resulting in peripheral vasodilation.


  4. ^ "Prazosin: Biological activity". IUPHAR. International Union of Basic and Clinical Pharmacology. Retrieved 3 June 2016.


  5. ^ Day, H. E.; Campeau, S.; Watson Jr, S. J.; Akil, H. (1997). "Distribution of alpha 1a-, alpha 1b- and alpha 1d-adrenergic receptor mRNA in the rat brain and spinal cord". Journal of Chemical Neuroanatomy. 13 (2): 115–139. doi:10.1016/S0891-0618(97)00042-2. PMID 9285356.


  6. ^ ab Shen, Howard (2008). Illustrated Pharmacology Memory Cards: PharMnemonics. Minireview. p. 13. ISBN 978-1-59541-101-3.


  7. ^ Kung S, Espinel Z, Lapid MI (2012). "Treatment of nightmares with prazosin: a systematic review". Mayo Clin. Proc. 87 (9): 890–900. doi:10.1016/j.mayocp.2012.05.015. PMC 3538493. PMID 22883741.


  8. ^ Bawaskar, H.S. & P.H. Bawaskar (2008). "Scorpion sting: A study of clinical manifestations and treatment regimes" (PDF). Current Science. 95 (9): 1337–1341. Retrieved 14 April 2010.


  9. ^ Bawaskar, H.S. & P.H. Bawaskar (2007). "Utility of scorpion anti-venin vs. prazosin in the management of severe Mesobuthus tamulus (Indian red scorpion) envenoming at rural settings" (PDF). JAPI. 55: 14–21. Retrieved 14 April 2010.


  10. ^ Pandi, K.; Krishnamurthy, S.; Srinivasaraghavan, R.; Mahadevan, S. (18 February 2014). "Efficacy of scorpion antivenom plus prazosin versus prazosin alone for Mesobuthus tamulus scorpion sting envenomation in children: a randomised controlled trial". Archives of Disease in Childhood. 99 (6): 575–580. doi:10.1136/archdischild-2013-305483. PMID 24550184.


  11. ^ Bhalla AK, Hoffbrand BI, Phatak PS, Reuben SR (October 1979). "Prazosin and priapism". Br Med J. 2 (6197): 1039. doi:10.1136/bmj.2.6197.1039. PMC 1596841. PMID 519276.


  12. ^ Simpson, TL; Saxon, AJ; Meredith, CW; Malte, CA; McBride, B; Ferguson, LC; Gross, CA; Hart, KL; Raskind, M (2009). "A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence". Alcoholism: Clinical and Experimental Research. 33 (2): 255–63. doi:10.1111/j.1530-0277.2008.00807.x. PMID 18945226.


  13. ^ Study of the Medication Prazosin for Alcohol Dependence


  14. ^ Simpson, Tracy L; Saxon, Andrew J; Stappenbeck, Cynthia; Malte, Carol A; Lyons, Robert; Tell, Dana; Millard, Steven P; Raskind, Murray (2018). "Double-Blind Randomized Clinical Trial of Prazosin for Alcohol Use Disorder". American Journal of Psychiatry: appi.ajp.2018.1. doi:10.1176/appi.ajp.2018.17080913. PMID 30153753.


  15. ^ S. Assad Kahn, S. L. Costa, S. Gholamin, R. T. Nitta, L. G. Dubois, M. Feve, M. Zeniou, P. L. C. Coelho, E. El-Habr, J. Cadusseau, P. Varlet, S. S. Mitra, B. Devaux, M.-C. Kilhoffer, S. H. Cheshier, V. Moura-Neto, J. Haiech, M.-P. Junier, H. Chneiweiss. (2016). The anti-hypertensive drug prazosin inhibits glioblastoma growth via the PKC -dependent inhibition of the AKT pathway. EMBO Molecular Medicine, doi:10.15252/emmm.201505421


  16. ^ Recycling an anti-hypertensive agent to fight brain tumors. ScienceDaily 21 April 2016















Retrieved from "https://en.wikipedia.org/w/index.php?title=Prazosin&oldid=858014468"





Navigation menu

























(window.RLQ=window.RLQ||).push(function(){mw.config.set({"wgPageParseReport":{"limitreport":{"cputime":"0.776","walltime":"0.972","ppvisitednodes":{"value":6094,"limit":1000000},"ppgeneratednodes":{"value":0,"limit":1500000},"postexpandincludesize":{"value":197445,"limit":2097152},"templateargumentsize":{"value":6905,"limit":2097152},"expansiondepth":{"value":17,"limit":40},"expensivefunctioncount":{"value":3,"limit":500},"unstrip-depth":{"value":1,"limit":20},"unstrip-size":{"value":42230,"limit":5000000},"entityaccesscount":{"value":3,"limit":400},"timingprofile":["100.00% 759.653 1 -total"," 61.40% 466.408 1 Template:Drugbox"," 45.11% 342.668 1 Template:Infobox"," 25.68% 195.109 1 Template:Reflist"," 17.51% 132.995 9 Template:Cite_journal"," 11.98% 91.014 16 Template:Unbulleted_list"," 11.21% 85.174 10 Template:Navbox"," 4.89% 37.142 1 Template:Infobox_drug/chemical_formula"," 4.09% 31.105 1 Template:EditAtWikidata"," 3.95% 30.007 1 Template:Anxiolytics"]},"scribunto":{"limitreport-timeusage":{"value":"0.280","limit":"10.000"},"limitreport-memusage":{"value":6385069,"limit":52428800}},"cachereport":{"origin":"mw1269","timestamp":"20181208191745","ttl":1900800,"transientcontent":false}}});});{"@context":"https://schema.org","@type":"Article","name":"Prazosin","url":"https://en.wikipedia.org/wiki/Prazosin","sameAs":"http://www.wikidata.org/entity/Q425296","mainEntity":"http://www.wikidata.org/entity/Q425296","author":{"@type":"Organization","name":"Contributors to Wikimedia projects"},"publisher":{"@type":"Organization","name":"Wikimedia Foundation, Inc.","logo":{"@type":"ImageObject","url":"https://www.wikimedia.org/static/images/wmf-hor-googpub.png"}},"datePublished":"2005-07-18T11:25:17Z","dateModified":"2018-09-04T14:29:46Z","image":"https://upload.wikimedia.org/wikipedia/commons/d/db/Prazosin.svg","headline":"chemical compound"}(window.RLQ=window.RLQ||).push(function(){mw.config.set({"wgBackendResponseTime":133,"wgHostname":"mw1263"});});
-

Popular posts from this blog

Full-time equivalent

Image
Full-time equivalent From Wikipedia, the free encyclopedia Jump to navigation Jump to search Full-time equivalent ( FTE ) or whole time equivalent ( WTE ) is a unit that indicates the workload of an employed person (or student) in a way that makes workloads or class loads comparable [1] across various contexts. FTE is often used to measure a worker's or student's involvement in a project, or to track cost reductions in an organization. An FTE of 1.0 is equivalent to a full-time worker or student, while an FTE of 0.5 signals half of a full work or school load. [2] Contents 1 U.S. Federal Government 2 In education 2.1 Example 3 Notes 4 References U.S. Federal Government [ edit ] In the U.S. Federal Government, FTE is defined by the Government Accountability Office (GAO) as the number of total hours worked divided by the maximum number of compensable hours in a full-time schedule as
Read more

Bicuculline

Image
Bicuculline From Wikipedia, the free encyclopedia Jump to navigation Jump to search Bicuculline Clinical data ATC code none Identifiers IUPAC name (6 R )-​6-​[(5 S )-​6-​methyl-​5,​6,​7,​8-​tetrahydro​[1,3]dioxolo​[4,5- g ]​isoquinolin-​5-​yl]​furo[3,4- e ]​[1,3]​benzodioxol-​8(6 H )-​one CAS Number 485-49-4   Y PubChem CID 10237 IUPHAR/BPS 2312 ChemSpider 9820   Y UNII Y37615DVKC ChEBI CHEBI:3092   N ChEMBL ChEMBL417990   N ECHA InfoCard 100.006.927 Chemical and physical data Formula C 20 H 17 N O 6 Molar mass 367.352 g/mol 3D model (JSmol) Interactive image Melting point 215 °C (419 °F) SMILES O=C1O[C@H](c3c1c2OCOc2cc3)[C@@H]5c4cc6OCOc6cc4CCN5C InChI InChI=1S/C20H17NO6/c1-21-5-4-10-6-14-15(25-8-24-14)7-12(10)17(21)18-11-2-3-13-19(26-9-23-13)16(11)20(22)27-18/h2-3,6-7,17-18H,4-5,8-9H2,1H3/t17-,18+/m0/s1   Y Key:IYGYMKDQCDOMRE-ZWKOTPCHSA-N
Read more

さくらももこ

Image
さくら ももこ 本名 非公開 [1] 生誕 ( 1965-05-08 ) 1965年5月8日 日本・静岡県清水市 （現・静岡市清水区） 死没 ( 2018-08-15 ) 2018年8月15日（53歳没） 日本・東京都目黒区 国籍 日本 職業 漫画家 エッセイスト 作詞家 活動期間 1984年 - 2018年 ジャンル 少女漫画 青年漫画 児童漫画 代表作 『ちびまる子ちゃん』 『コジコジ』 受賞 1989年：第13回講談社漫画賞少女部門 （『ちびまる子ちゃん』） 1990年：第32回日本レコード大賞 （『おどるポンポコリン』作詞） 公式サイト さくらプロダクション テンプレートを表示 さくら ももこ （1965年5月8日 - 2018年8月15日 [2] ）は、日本の漫画家、エッセイスト、作詞家、脚本家。また、自身の少女時代をモデルとした代表作のコミック『ちびまる子ちゃん』の主人公の名前でもある。静岡県清水市（現・静岡市清水区）出身。血液型はA型。身長159cm。一男の母親。 代表作のコミック『ちびまる子ちゃん』の単行本の売上は累計3000万部を超える。また、エッセイストとしても独特の視点と語り口で人気が高く、初期エッセイ集三部作『もものかんづめ』『さるのこしかけ』『たいのおかしら』はいずれもミリオンセラーを記録。 目次 1 経歴 2 人物・交遊関係 3 主な作品 3.1 漫画 3.2 エッセイ 3.3 作詞 3.4 詩集 3.5 雑誌・ムック本 3.6 翻訳 3.7 絵本、ドラマ脚本他 3.8 ラジオ出演 3.9 その他 4 関係人物 4.1 アシスタント 4.2 さくらももこを演じた人物 5 脚注 5.1 注釈 5.2 出典 6 外部リンク 経歴 年譜形式の経歴は推奨されていません 。人物の伝記は流れのあるまとまった文章で記述し、年譜は補助的な使用にとどめてください。 （ 2018年8月 ） 清水市立（当時）入江小学校
Read more